Photo activated ruthenium-containing polymer micelles to overcome multidrug resistance
Date issued
Authors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
License
Abstract
Cancer is one of the leading causes of human death in the world. Although significant
improvement has been made in chemotherapy for cancer treatment, complete
regression is still challenging. A great obstacle in chemotherapy is the acquired
resistance when chemotherapeutics are used, inducing tumor recurrence and
therapeutic failure. A main mechanism of multidrug resistance (MDR) is via expression
of drug efflux transporters on the surface of tumor cells such as permeability
glycoprotein (P-gp). They not only inhibit the uptake of chemotherapeutics, but also
pumps them out from tumor cells. Moreover, high systemic toxicity of
chemotherapeutics is another problem that hurdles the clinical treatment of cancer.
The development of nanocarriers brings new hope for chemotherapy. They exhibit a
long circulation time in the bloodstream and can deliver drugs to tumor cells through
nanotechnology-mediated passive or active targeting. What is important, in the process
of uptake: nanocarriers can bypass P-gp so that the drugs are not recognized by P-gp as
substrates. Thus, the drugs escape from the capture of the transporters, allowing a high
intracellular drug accumulation. Although substantial progress has been made using
nanocarriers, the entire eradication and cure of cancer remains a challenge.
Nanocarriers need combine with other strategies to overcome MDR.
Compared to other external stimuli, light-triggered drug release has the potential
advantage of its noninvasive nature and ease of spatiotemporal control. Most
phototherapy studies used ultraviolet (UV) light or short-wavelength visible light to
trigger the release of drugs. However, the depth of light penetration into tissue depends
on the wavelength. When setting the the same light intensity, the light penetrates only
~1.00 mm at wavelength of 408 nm, but ~6.3 mm at wavelength of 633 nm and ~7.5
mm at wavelength of 705 nm. UV light or short-wavelength visible light not only shows
limited penetration depth into tissue but also has the risk of photodamage to biological
systems. In contrast, red or near infrared radiation (NIR) light can penetrate deeper into
tissue and cause less photodamage, which is more suitable for in vivo applications.
The success of platinum (Pt) complexes such as cisplatin in cancer treatment
motivates the development of new metallodrugs. Some Ruthenium (Ru) complexes are
promising metallodrugs for anticancer therapy. More than three of them are in clinical
trials. Photoactivation is a way to improve selectivity of Ru complexes in cancer therapy.
Some of them are responsive to red or NIR light. The successful delivery of
photoactivatable Ru complexes to cancer cells requires that they must be stable in the
dark under physiological conditions. However, the ligands of photoactivatable Ru complexes may be substituted by water and biomolecules such as dissolved proteins
before they are delivered to cancer cells.
Therefore, the question arise: what need to do for overcoming MDR of cancer cells
more efficiently? Combined nanocarriers with phototherapy of Ru complexes using red
light may settle this problem. The aim of this thesis is a prerequisite to answer the
question, namely to improve the stability of photoactivatable Ru complexes under
physiological conditions.
In this thesis, I first systematically studied the stabilities of two Ru-containing block
polymers and their corresponding Ru complexes under imitated physiological
conditions. I concluded from results that in the different media, the corresponding Ru
complexes were stabilized by their Ru-containing polymer assemblies, which made
these assemblies potential candidates for biomedical applications.
Then, red-light-triggered Ru-containing block copolymer (PEG-b-P(CPH-co-
RuCHL)) micelles with doxorubicin (DOX) encapsulation (DOX@PEG-b-P(CPH-co-
RuCHL)) were designed. Red light induced the destruction of DOX@PEG-b-P(CPH-
co-RuCHL) micelles, resulting in the release of Ru complexes and DOX simultaneously.
Finally, DOX@PEG-b-P(CPH-co-RuCHL) micelles were used to overcome MDR.
After bypass P-gp, DOX@PEG-b-P(CPH-co-RuCHL) micelles were accumulated in
drug-resistant Michigan Cancer Foundation-7 (MCF-7R) breast cells. The intracellular
release of DOX was controlled by red light. Deoxyribonucleic acid (DNA) damage was
caused via DOX interacted with DNA by intercalation and Ru complexes crosslinked
with DNA by photobinding. I also studied the effect of overcoming MDR in vitro and
in vivo. DOX@PEG-b-P(CPH-co-RuCHL) micelles that were activated by red light
irradiation induced the significant death of MCF-7R cells and the excellent inhibition
of the growth of MCF-7R tumor. I believe that the design of the controlled release of
dual drugs from red-light-responsive Ru-containing polymer micelles will open up an
avenue for photochemotherapy to overcome MDR.